---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008560"
form_type: "8-K"
ticker: "TCMD"
cik: "0001027838"
company_name: "TACTILE SYSTEMS TECHNOLOGY INC"
filed_at: "2023-05-08T23:59:59+00:00"
generated_at: "2026-06-15T11:51:50.348389+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tactile Medical Q1 revenue up 23% to $58.8M; raises FY2023 guidance to $271-275M

## Summary
- Q1 revenue $58.8M (+23% YoY); net loss narrowed to $1.9M ($0.09 diluted) from $15.6M loss ($0.78).
- Lymphedema revenue +22%, airway clearance +24%; gross margin 70.5%.
- Adjusted EBITDA turned positive to $0.5M from ($2.6M) loss in Q1 2022.
- FY2023 revenue guidance raised to $271-275M (prior $269-273M), growth ~10-11.5%.
- Closed public equity offering raising $34.6M net; appointed Elaine Birkemeyer as CFO.

## SEC filing metadata
- accession: 0001558370-23-008560
- form_type: 8-K
- ticker: TCMD
- cik: 0001027838
- company_name: TACTILE SYSTEMS TECHNOLOGY INC
- filed_at: 2023-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/0001558370-23-008560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/tcmd-20230508x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008560
- JSON: https://secwatch.observer/filing/0001558370-23-008560.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008560.txt

## Key facts
- Earnings Releases
  TACTILE SYSTEMS TECHNOLOGY INC reported first quarter ended March 31, 2023 results: revenue $58.8 million, net income Net loss of $1.9 million, or $0.09 per diluted share, EPS $0.09 per diluted share. Guidance raised.
  - Period: first quarter ended March 31, 2023
  - Revenue: $58.8 million
  - Net income: Net loss of $1.9 million, or $0.09 per diluted share
  - EPS: $0.09 per diluted share
  - Guidance: raised
  - Result: reported results
  source text: with chronic disorders , today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary: ● Total revenue increased 23% year-over-year to $58.8 million ● Lymphedema products revenue increased 22% year-over-year ● Airway clearance products revenue increased 24% year-over-year ● Operating loss of $3.8 million versus $14.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1027838/000155837023008560/0001558370-23-008560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.